PC cell-derived growth factor overexpression promotes proliferation and survival of laryngeal carcinoma.

Abstract:

:PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to evaluate the clinical significance of PC cell-derived growth factor and the potential of small interfering RNA-induced genetic silencing of PC cell-derived growth factor as a supplementary therapeutic way for laryngeal squamous cell carcinoma. A total of 146 primary laryngeal cancer, 108 adult laryngeal papilloma and 41 laryngeal leukoplakia samples, as well as 10 normal larynx tissues were investigated. The PC cell-derived growth factor mRNA level was examined by real-time polymerase chain reaction and protein localization by immunohistochemistry. The biological function of PC cell-derived growth factor was assessed by transfection of small interfering RNA PC cell-derived growth factor construction. The PC cell-derived growth factor protein levels and mRNA levels of the laryngeal squamous cell carcinomas were significantly higher than those of normal laryngeal tissues (P<0.001). Simultaneously, the difference in the levels of mRNA and protein between those of laryngeal precancerous lesions (papilloma/leukoplakia) and those of normal tissues was significant (P<0.05, P<0.05), whereas those of laryngeal precancerous lesions (papilloma/leukoplakia) were significantly lower than those of laryngeal squamous cell carcinomas (P<0.05, P<0.05). Strong PC cell-derived growth factor expression was associated with lymph node metastases in laryngeal squamous cell carcinoma (P<0.05). Functional studies on Hep-2 cell lines demonstrated that the attenuation of PC cell-derived growth factor expression levels led to diminished cell proliferation rates (P<0.001), anchorage-independent growth in vitro (P<0.001), tumor forming in vivo (P<0.01) and resistance to apoptosis (P<0.001). PC cell-derived growth factor is a pivotal autocrine growth factor in the tumorigenesis of laryngeal squamous cell carcinoma. Our findings also indicate that PC cell-derived growth factor is a logical and potential target for early diagnosis, specific therapy and prognosis of laryngeal squamous cell carcinoma.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

doi

10.1097/01.cad.0000236315.96574.58

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

29-40

issue

1

eissn

0959-4973

issn

1473-5741

pii

00001813-200701000-00005

journal_volume

18

pub_type

杂志文章
  • The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.

    abstract::Low doses of drugs delivered at close, regular intervals are increasingly being used to manage patients with different neoplasms. Despite the good tolerability, treatment-related adverse events still occur following metronomic protocols. The aim of this study was to retrospectively investigate whether polymorphisms of...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000429

    authors: Romiti A,Roberto M,D'Antonio C,Onesti CE,Barucca V,Milano A,Gentile G,Lionetto L,Medda E,Mazzuca F,Botticelli A,Falcone R,Simmaco M,Marchetti P

    更新日期:2016-11-01 00:00:00

  • Capecitabine: a novel agent for the treatment of solid tumors.

    abstract::Although 5-fluorouracil (5-FU) has been used to treat breast and colorectal cancers for several decades, bolus 5-FU has disappointing efficacy. Prolonged infusion schedules and biomodulation with leucovorin have resulted in improved response rates, but these have not translated into significant improvements in surviva...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200109000-00001

    authors: Johnston PG,Kaye S

    更新日期:2001-09-01 00:00:00

  • Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.

    abstract::Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199710000-00004

    authors: Stehle G,Wunder A,Sinn H,Schrenk HH,Schütt S,Frei E,Hartung G,Maier-Borst W,Heene DL

    更新日期:1997-10-01 00:00:00

  • Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer.

    abstract::This study aims to explore the effect and mechanism of pyruvate kinase M2 (PKM2) on chemotherapy resistance of estrogen receptor-positive breast cancer (ER BC) by regulating aerobic glycolysis. The expression of PKM2 in ER BC MCF-7 cells, T47D cells and MCF-7/ADR cells (which are subject to adriamycin/ADR induction) w...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000624

    authors: Qian Y,Bi L,Yang Y,Wang D

    更新日期:2018-08-01 00:00:00

  • Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.

    abstract::Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. Th...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000231468.69535.97

    authors: Olbert PJ,Hegele A,Kraeuter P,Heidenreich A,Hofmann R,Schrader AJ

    更新日期:2006-09-01 00:00:00

  • Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.

    abstract::In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX) is being studied. The NGR peptide on the surface of liposomal doxorubicin (DOX) targets an aminopeptidase N (CD13) isoform, specific to the tumor neovasculatur...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3282a213ce

    authors: Garde SV,Forté AJ,Ge M,Lepekhin EA,Panchal CJ,Rabbani SA,Wu JJ

    更新日期:2007-11-01 00:00:00

  • Mechanism of action of rituximab.

    abstract::The CD20 antigen is strongly and stably expressed on cells of the B-cell lineage, but not on stem cells, and is thus an ideal target antigen for antibody therapy of B-cell malignancies. Rituximab is a human-mouse chimeric monoclonal antibody to the CD20 antigen that kills B-cells by a number of different effector mech...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Maloney DG

    更新日期:2001-06-01 00:00:00

  • A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.

    abstract::The aim of this study was to investigate in a randomized trial the activity of perioperative chemotherapy in patients treated with preoperative chemotherapy for locally advanced breast cancer and to compare it with the preoperative chemotherapy alone. Patients with cT2-3 N0-2 M0 histologically proven breast cancer, wi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.cad.0000236306.43209.2b

    authors: Rocca A,Peruzzotti G,Ghisini R,Viale G,Veronesi P,Luini A,Intra M,Pietri E,Curigliano G,Giovanardi F,Maisonneuve P,Goldhirsch A,Colleoni M

    更新日期:2006-11-01 00:00:00

  • Silibinin affects tumor cell growth because of reduction of stemness properties and induction of apoptosis in 2D and 3D models of MDA-MB-468.

    abstract::Silibinin, with a strong antioxidant activity and a weak cytotoxic property, is considered a candidate for cancer prevention. As there is no information on its effect on breast cancer tumor-initiating cells [cancer stem cells (CSCs)] in a 3D culture model, which more closely mimic natural tissues, we carried out this ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000205

    authors: Abdollahi P,Ebrahimi M,Motamed N,Samani FS

    更新日期:2015-06-01 00:00:00

  • Chitosan nanoparticles for dermaseptin peptide delivery toward tumor cells in vitro.

    abstract::The present study aimed to entrap and characterize the morphology and antitumor effects of a dermaseptin (DStomo01) peptide in chitosan nanoparticles, in vitro. DStomo01 nanoparticles showed moderate polydispersivity, excellent colloidal stability, and slow release. It was noted that free DStomo01 induced DNA fragment...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000052

    authors: Medeiros KA,Joanitti GA,Silva LP

    更新日期:2014-03-01 00:00:00

  • Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.

    abstract::Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32834bede5

    authors: Pouessel D,Culine S

    更新日期:2012-01-01 00:00:00

  • The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay.

    abstract::The use of viability assays to assess the effect of antineoplastic agents on cell lines and tumor cells is an important investigative tool and may have clinical relevance. Such assays require very small quantities of drugs and it is the practice of many laboratories to freeze aliquots of drugs for use in these assays ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199404000-00007

    authors: Hunter EM,Sutherland LA,Cree IA,Subedi AM,Hartmann D,Linder D,Andreotti PE

    更新日期:1994-04-01 00:00:00

  • Generation and characterization of a paclitaxel-resistant human gastric carcinoma cell line.

    abstract::The main aim of this study was to establish a novel paclitaxel (PTX)-resistant human gastric carcinoma cell line and to investigate its biological significance. A cell line, MGC803/PTX, was established by gradually increasing PTX density on the basis of MGC803 over a period of 10 months. In addition, a pair of resista...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000601

    authors: Fu L,Yin F,Li XR,Han BK,Zhang C,Wang JW,Wang YQ,Bi YF,Liu HM

    更新日期:2018-07-01 00:00:00

  • S-allylcysteine induces cytotoxic effects in two human lung cancer cell lines via induction of oxidative damage, downregulation of Nrf2 and NF-κB, and apoptosis.

    abstract::In this study, we investigated the putative cytotoxic effect elicited by the garlic-derived compound S-allylcysteine (SAC) in two human cancer cell lines (HCC827 and NCI-H1975) in order to develop an experimental approach to the therapeutic potential of this molecule for lung cancer. Cells were incubated for 24, 48 an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000001015

    authors: Orozco-Morales M,Hernández-Pedro NY,Barrios-Bernal P,Arrieta O,Ruiz-Godoy LM,Aschner M,Santamaría A,Colín-González AL

    更新日期:2021-02-01 00:00:00

  • Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

    abstract::A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200206000-00007

    authors: Gedlicka C,Schüll B,Formanek M,Kornfehl J,Burian M,Knerer B,Selzer E,Scheithauer W,Kornek GV

    更新日期:2002-06-01 00:00:00

  • Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature.

    abstract::Neurofibromatosis type 2 (NF2) is an autosomal dominant condition caused by pathogenic variants in the NF2 gene. To date, cytotoxic chemotherapy has no established role in the treatment of NF-2. Historical case reports of malignant schwannomas have documented responses to chemotherapies with cyclophosphamide, vincrist...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000953

    authors: Nigro O,Coppola A,Tartaro T,Tuzi A,Vallini I,Pinotti G

    更新日期:2020-08-01 00:00:00

  • Liver X receptor as a drug target for the treatment of breast cancer.

    abstract::Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000348

    authors: Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

    更新日期:2016-06-01 00:00:00

  • Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis.

    abstract::Esophageal cancer is one of the fatal cancers around the world. Dexmedetomidine (DEX) is widely used during anesthesia of esophageal cancer surgery. Nevertheless, the role of DEX in the progression of esophageal cancer remains barely known. The proliferation, apoptosis and metastasis of esophageal cancer cells were de...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000934

    authors: Zhang P,He H,Bai Y,Liu W,Huang L

    更新日期:2020-08-01 00:00:00

  • Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.

    abstract::High concentrations of specific catechins [epigallocatechin gallate (EGCG), epigallocatechin (EGC) and epicatechin gallate (ECG)] inhibit the proliferation of many different cancer cell lines. The aim of this work was to determine if low concentrations of catechins with and without 4-hydroxytamoxifen (4-OHT) co-treatm...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200410000-00010

    authors: Chisholm K,Bray BJ,Rosengren RJ

    更新日期:2004-10-01 00:00:00

  • Aspirin reduces adverse effects of gefitinib.

    abstract::We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib. The serum levels of sP-selectin and TxB2 increased significantly in all patients who received gefitinib...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.cad.0000203385.45163.76

    authors: Kanazawa S,Yamaguchi K,Kinoshita Y,Muramatsu M,Komiyama Y,Nomura S

    更新日期:2006-04-01 00:00:00

  • Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility.

    abstract::Imexon is an investigational anti-cancer agent, pharmaceutically formulated as a lyophilized solid for i.v. infusion requiring reconstitution and subsequent dilution in infusion fluid before infusion. Imexon contains a highly reactive aziridine ring in its structure, which limits its stability in aqueous solutions. In...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000172833.70444.ba

    authors: den Brok MW,Nuijen B,Challa EE,Lutz C,Opitz HG,Beijnen JH

    更新日期:2005-08-01 00:00:00

  • Effect of membrane active 1-alkylpiperidine N-oxides on glycolysis, respiration and ATP level in tumor cells.

    abstract::The aim of this study was to study the effect of the homologous series of 1-alkylpyrrolidine N-oxides on ATP-producing processes in Ehrlich ascites and L1210 murine leukemia cells. 1-Decylpiperidine N-oxide (deP-NO), one of the active compounds, significantly stimulated the course of aerobic glycolysis of Ehrlich cell...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199308000-00008

    authors: Miko M,Devinsky F

    更新日期:1993-08-01 00:00:00

  • Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.

    abstract::Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328344887f

    authors: Boehrer S,Schroeder P,Mueller T,Atz J,Chow KU

    更新日期:2011-07-01 00:00:00

  • Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin.

    abstract::The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7 resistant to adria...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000529

    authors: Chen Q,Meng YQ,Xu XF,Gu J

    更新日期:2017-09-01 00:00:00

  • Modulation of melphalan cytotoxic activity in human melanoma cell lines.

    abstract::The aim of the present study was to potentiate the cytotoxic effects of melphalan through pharmacological and physical modulators. The combination of the cytotoxic agent with ethacrynic acid, a glutathione-S-transferase pi (GST pi) inhibitor, or topotecan, a topoisomerase I inhibitor, or mild hyperthermia was investig...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199607000-00017

    authors: Supino R,Caserini C,Orlandi L,Zaffaroni N,Silvestrini R,Vaglini M,Zunino F

    更新日期:1996-07-01 00:00:00

  • Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer.

    abstract::The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199104000-00005

    authors: Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

    更新日期:1991-04-01 00:00:00

  • No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.

    abstract::We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction. Plasma concentrations of nevirapine (dose: 200 mg twice daily orally) and paclitaxel (dose: 100 mg/m(...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200507000-00006

    authors: Kappelhoff BS,Huitema AD,Mairuhu AT,Schellens JH,Beijnen JH

    更新日期:2005-07-01 00:00:00

  • Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Stud

    abstract::A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3282fb178a

    authors: Hejna M,Raderer M,Zacherl J,Ba-Ssalamah A,Püspök A,Schmidinger M,Pluschnig U,Brodowicz T,Zielinski CC

    更新日期:2008-06-01 00:00:00

  • Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.

    abstract::Our objective was to determine the maximum tolerated dose (MTD) of paclitaxel when given as a 7 day continuous i.v. infusion, repeated every 3 weeks, and to evaluate the toxicity and the efficacy of such a schedule of administration as a salvage treatment in ovarian cancer patients pretreated and refractory to 3 or 24...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199709000-00005

    authors: Soulié P,Trandafir L,Taamma A,Lokiec F,Brain E,Delord JP,Mita A,Vannetzel JM,Cvitkovic E,Misset JL

    更新日期:1997-09-01 00:00:00

  • A novel bis-aryl urea compound inhibits tumor proliferation via cathepsin D-associated apoptosis.

    abstract::Derivatives of bis-aryl urea have been widely investigated for their various biological activities, such as antiviral, anti-inflammatory and antiproliferative. We evaluated a new chemical entity consisting of bis-aryl urea moiety, N69B, for its anticancer activities and explored their underlying molecular mechanism. T...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000898

    authors: Wu J,Huang Y,Xie Q,Zhang J,Zhan Z

    更新日期:2020-06-01 00:00:00